Srikripa Devarakonda
Stock Analyst at Truist Securities
(3.64)
# 821
Out of 4,623 analysts
44
Total ratings
58.14%
Success rate
4.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Maintains: Buy | $1,000 → $1,033 | $932.06 | +10.83% | 3 | Oct 10, 2024 | |
| ABBV AbbVie | Maintains: Buy | $210 → $215 | $194.19 | +10.72% | 1 | Oct 10, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $54 | $10.78 | +400.93% | 1 | Sep 27, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $1,200 | $1,015.67 | +18.15% | 2 | Sep 24, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $25 → $33 | $31.92 | +3.38% | 5 | Sep 19, 2024 | |
| INCY Incyte | Downgrades: Hold | $83 → $74 | $66.12 | +11.92% | 8 | Sep 18, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Buy | $60 | $45.08 | +33.10% | 1 | Sep 9, 2024 | |
| VSTM Verastem | Maintains: Buy | $18 → $15 | $2.97 | +405.05% | 7 | Aug 13, 2024 | |
| BIIB Biogen | Reiterates: Buy | $340 → $302 | $188.38 | +60.31% | 1 | Aug 5, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $36 | $23.63 | +52.35% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 | $59.78 | +67.28% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $54.88 | +27.55% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $26.51 | -24.56% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $54 | $45.02 | +19.95% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $3.00 | +1,900.00% | 2 | Aug 11, 2023 |
Eli Lilly
Oct 10, 2024
Maintains: Buy
Price Target: $1,000 → $1,033
Current: $932.06
Upside: +10.83%
AbbVie
Oct 10, 2024
Maintains: Buy
Price Target: $210 → $215
Current: $194.19
Upside: +10.72%
Biomea Fusion
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $10.78
Upside: +400.93%
Regeneron Pharmaceuticals
Sep 24, 2024
Reiterates: Buy
Price Target: $1,200
Current: $1,015.67
Upside: +18.15%
Edgewise Therapeutics
Sep 19, 2024
Maintains: Buy
Price Target: $25 → $33
Current: $31.92
Upside: +3.38%
Incyte
Sep 18, 2024
Downgrades: Hold
Price Target: $83 → $74
Current: $66.12
Upside: +11.92%
Protagonist Therapeutics
Sep 9, 2024
Initiates: Buy
Price Target: $60
Current: $45.08
Upside: +33.10%
Verastem
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $2.97
Upside: +405.05%
Biogen
Aug 5, 2024
Reiterates: Buy
Price Target: $340 → $302
Current: $188.38
Upside: +60.31%
Nurix Therapeutics
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $23.63
Upside: +52.35%
Jun 18, 2024
Maintains: Buy
Price Target: $100
Current: $59.78
Upside: +67.28%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $54.88
Upside: +27.55%
Apr 3, 2024
Reiterates: Buy
Price Target: $20
Current: $26.51
Upside: -24.56%
Mar 1, 2024
Maintains: Buy
Price Target: $41 → $54
Current: $45.02
Upside: +19.95%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $3.00
Upside: +1,900.00%